The trial assessed the use of the DX-ICD system for remotely monitoring atrial high-rate episodes and their duration progression. Credit: BIOTRONIK.

Biotronik announced that the MATRIX study has demonstrated the high detection accuracy of DX single-lead implantable cardioverter-defibrillator (ICD) systems for atrial fibrillation (AF) in single-chamber ICD patients.

The system, together with the company’s Home Monitoring solution, enabled the guideline-recommended remote monitoring of subclinical AF.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial assessed the ability of the DX-ICD system (atrial signal detection via a floating dipole integrated in the ICD lead) to remotely monitor atrial high-rate episodes (AHRE) and their duration progression.

Furthermore, the clinical implications of AHRE detection and progression were also evaluated as part of the study.

Biotronik chief medical officer David Hayes said: “As the largest clinical evaluation of the DX Technology to date, the MATRIX study has clearly proven, under real-world conditions, that DX-ICDs together with Biotronik Home Monitoring can provide clinically-relevant benefits that support physicians in making the right decisions for their single-chamber ICD patients – timely and consistent with current medical guidelines.”

See Also:

The study was led by Gerhard Hindricks from Deutsches Herzzentrum der Charité and Andreas Bollmann from the Heart Center Leipzig at the University of Leipzig and Helios Health Institute, Germany.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The international and multicentre trial recruited 2,054 DX-ICD patients in 119 sites across 24 countries. Patients have been followed for two years under real-life conditions.

In a statement, Hindricks said: “Our analysis shows that you can detect and monitor AHRE with high accuracy in single-chamber ICD patients using DX Technology.

“Together with the proven transmission reliability of Home Monitoring, this supports a reliable AHRE burden monitoring, as recommended by current guidelines.”